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To assess the occurrence of perinatal depression and anxiety in women before and after
diagnosis of multiple sclerosis (MS).
Methods
A total of 114,629 pregnant women were included in the Norwegian Mother, Father and Child
Cohort study (1999–2008). We assessed depression and anxiety by questionnaires during and
after pregnancy. Women with MS were identified from national health registries and hospital
records and grouped into (1) MS diagnosed before pregnancy (n = 140) or MS diagnosed after
pregnancy with (2) symptom onset before pregnancy (n = 98) or (3) symptom onset after
pregnancy (n = 308). Thirty-five women were diagnosed with MS in the postpartum period.
The reference group (n = 111,627) consisted of women without MS.
Results
Women with MS diagnosed before pregnancy had an adjusted odds ratio of 2.0 (95% confi-
dence interval, 1.2–3.1) for depression in the third trimester. Risk factors were adverse so-
cioeconomic factors and history of psychiatric disease and physical/sexual abuse. The risk of
anxiety was not increased. Women diagnosed with MS in the postpartum period had especially
high risk of postpartum depression. Women with MS symptom onset within 5 years after
pregnancy had increased risk of both depression and anxiety during pregnancy, whereas women
with more than 5 years until symptom onset did not.
Conclusion
Women diagnosed with MS have increased risk of perinatal depression. Women with MS
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People with multiple sclerosis (MS) have an increased prev-
alence of depression and anxiety compared to the general
population.1 Several factors contribute, including pathobio-
logical mechanisms of MS itself.2,3 Perinatal depression is the
most common complication of pregnancy and is often
underrecognized. It is defined as depression during pregnancy
and up to 1 year after birth.4-6
There is limited knowledge of the occurrence of depression
and anxiety in the perinatal setting among women with MS.
One study found that 26% of mothers and fathers with MS
had depression or anxiety in relation to pregnancy,7 compared
to 19% of parents without MS. Psychiatric comorbidity in
mothers influence mental health and developmental vulner-
ability in children.8-10 Because mothers with MS are at in-
creased risk of depression and anxiety, it is important to
identify risk factors associated with these symptoms in the
perinatal setting to provide optimal prevention, treatment,
and follow-up for women at risk.
Our primary aim was to investigate the occurrence of de-
pression and anxiety during pregnancy and 6 months post-
partum. We studied (1) women with an established MS
diagnosis, (2) women who had experienced MS symptoms
but not yet received a diagnosis, and (3) women with clinical
MS symptom onset in the subsequent months or years after
giving birth. The last 2 groups were included as they might
have had subclinical or prodromal manifestations of MS
during the perinatal period.11-13 Our secondary aim was to
investigate to what degree MS-related factors and psychoso-
cial aspects influenced the occurrence of these symptoms.
Methods
Study Design and Population
This is a prospective, population-based cohort study that in-
cludes women participating in the Norwegian Mother, Father
and Child Cohort study (MoBa). The MoBa study is con-
ducted by the Norwegian Institute of Public Health and is
linked to the Medical Birth Registry of Norway (MBRN), to
which registration is mandatory for Norwegian health care
providers.14 Participants were recruited from all over Norway
from 1999 through 2008. All Norwegian-speaking women
were invited to the study after the routine ultrasound exam-
ination in pregnancy week 15–17. There were no exclusion
criteria. In total, 50 of 52 maternity units with over 100 births
per year participated, and 41% of the invited women con-
sented to participation. Follow-up of the cohort is ongoing.
Our current study is based on version 12 of the quality-
assured data files released for research on September 5, 2019.
We obtained information on demography, socioeconomic
factors, medical history, and symptoms of anxiety and de-
pression by self-completed questionnaires. We used the
questionnaires answered during pregnancy weeks 17–20 and
30, and 6 and 18 months postpartum.
The MS diagnoses reported in the questionnaires were vali-
dated through data linkage with the Norwegian Multiple
Sclerosis Registry and Biobank (MSR), which also provided
information on MS subtype and date of symptom onset and
diagnosis.15 The MSR had 60% coverage of MS cases in
Norway at the time of linkage. To validate cases not registered
in MSR, the cohort was linked to the Norwegian Patient
Registry (NPR). The registration of patients in NPR is man-
datory for health practitioners, and all consultations with anMS
diagnosis in Norwegian specialist care have been registered
since March 2007 (data available from Dryad, figure e-1, doi.
org/10.5061/dryad.g4f4qrfpkv). TheMS diagnosis in NPR has
previously been validated, with a sensitivity of 97% and positive
predictive value 0.92.16 MS diagnoses registered in NPR, but
not in the MSR, were validated with information from hospital
records using the 2017 diagnostic criteria for MS.17
The linkage between health registries made it possible to
identify women with MS who failed to report a history of MS
at inclusion in MoBa, as well as women diagnosed with MS
after pregnancy. We followed these women until December
31, 2018. To differentiate between women with early symp-
tomatic yet undiagnosed MS and women with inactive (pre-
clinical) disease during pregnancy, we divided those
diagnosed withMS after pregnancy according to the timing of
their first MS symptoms. Hence, we defined 3 main groups:
(1) MS diagnosed before pregnancy, (2) MS diagnosed after
pregnancy with symptom onset before pregnancy, (3) MS
diagnosed after pregnancy with symptom onset after preg-
nancy (figure 1). The reference group consisted of all women
in MoBa without MS.
We also defined a subgroup of women who were diagnosed
with MS during the first 18 months after pregnancy. In
Glossary
aOR = adjusted odds ratio; CI = confidence interval; EPDS = Edinburgh Postnatal Depression Scale; HPA = hypothalamic-
pituitary-adrenal axis; HSCL-25 = Hopkins Symptom Checklist 25; LTMD = lifetime history of major depression; MBRN =
Medical Birth Registry of Norway; MoBa = Norwegian Mother, Father and Child Cohort Study; MS = multiple sclerosis;
MSR = Norwegian Multiple Sclerosis Registry and Biobank; NPR = Norwegian Patient Registry; OR = odds ratio; REK =
Regional Committee for Medical and Health Research Ethics; SCL-4A = Symptom Checklist 4-item anxiety subscale; SCL-
4D = Symptom Checklist 4-item depression subscale.
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addition to being compared with the reference group, these
women were also compared with a subgroup of the reference
group that reported, at the 18-month assessment, that they
had been diagnosed with a chronic disease other than MS
during the last 12 months.
We excluded women with uncertain or refuted MS diagnosis,
pregnancies with missing child number, and duplicate ques-
tionnaires from multiple gestations to include only one
observation per pregnancy (figure 2). Women who were
pregnant 18 months postpartum were excluded from the
analysis at 18 months after birth.
Primary Outcome Measure
Depression and anxiety were measured separately by vali-
dated short versions of the Hopkins Symptom Checklist 25
(HSCL-25).18-20 These are widely used screening tools
designed to detect depression and anxiety. The subscale SCL-
Figure 2 Flowchart of Excluded and Included Cases
Pregnancies included in the Norwegian Mother, Father and Child Cohort (MoBa) study version 12. MS = multiple sclerosis; Q = questionnaire.
Figure 1 Multiple Sclerosis (MS) Diagnosis and Symptom Onset in Relation to Pregnancy and Childbirth
We identified 546womenwithMS from theNorwegianMother, Father andChild Cohort (MoBa).Womenwere divided into 3 groups defined by theirMS status
on inclusion. The periods of establishedMS diagnosis are illustrated by colored arrows. Periods of symptomonset are shownwith dotted lines for the groups
with MS diagnosed after pregnancy. We also studied a subgroup of women who were diagnosed with MS in the postpartum period (0–18 months). aMS
diagnosed up to pregnancy weeks 18–20.
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8 includes 4 items capturing symptoms of depression (SCL-
4D) and 4 capturing symptoms of anxiety (SCL-4A),
screening for symptoms during the last 2 weeks before as-
sessment (data available from Dryad, e-Questionnaire, doi.
org/10.5061/dryad.g4f4qrfpkv). Items were scored on a
Likert scale ranging from 1 (“not at all bothered”) to 4 (“very
much bothered”). We used a validated mean score of >1.75 as
cutoff for presence of depression or anxiety, respectively.18,21
SCL-8 was used in pregnancy week 30 and 6 and 18 months
postpartum. We defined perinatal depression or anxiety as
symptoms occurring during pregnancy or in the postpartum
period up to 6 months after birth. The proportion of women
with symptoms was interpreted as the point prevalence of
either depression or anxiety. Scores from the 18-month as-
sessment were used as a prognostic measure for women with
MS before pregnancy (group 1) and as point prevalence for
those diagnosed with MS 0–18 months after birth.
Postpartum depression based on SCL-4D scores 6 months
after birth was validated with a 6-item version of the Edin-
burgh Postnatal Depression Scale (EPDS-6)22 with a
threshold score of ≥7/18 defining postpartum depression.23
The kappa agreement between SCL-4D and EPDS-6 was 88%
within the MS groups in this study, with a coefficient of 0.52.
A prior validation of the entire MoBa cohort showed 91%
overall agreement of SCL-4D and EPDS-6 at 6 months
postpartum.24
Covariates
MS-specific covariates were assessed from the MSR and
hospital records: time of MS onset, defined as first clinical
symptom; time of MS diagnosis; and subtype of MS
(relapsing-remitting MS, primary progressive MS, or un-
specified) at disease onset. Relevant covariates that have been
identified as possible risk factors for perinatal depression25,26
were selected from the MoBa questionnaires and the MBRN:
maternal age at inclusion, parity (pregnancies >24 gestational
weeks), low household income (<60% of median income in
the given year), short education (≤9 years), single mother,
unplanned pregnancy, overweight (prepregnancy body mass
index >25), smoking and alcohol use during pregnancy (≥1
consumption per month for each), and disability benefits such
as social security disability or work assessment allowance.
Comorbidities included asthma, prepregnancy hypertension,
renal disease, rheumatoid arthritis, type 1 diabetes, and epi-
lepsy, which are the available diagnoses in the MBRN and
registered by health personnel. Adverse pregnancy events
were defined as a prior history of stillbirth or miscarriage past
12 weeks, prior or current preeclampsia, and first trimester
vaginal bleeding. Adverse life events were defined as having
experienced one of the following and defining it as “painful or
difficult” during the last 12 months: conflict at work or study,
financial problems, divorce/separation/partnership breakup,
conflict with family or friends, severe injury or illness in the
woman herself or a loved one, severe traffic accident, fire or
robbery, or death of a close relative or friend. Lifetime physical
and sexual abuse was evaluated by questions adapted from the
Abuse Assessment Screen.27 A history of major depression
was assessed by the lifetime major depression score
(LTMD).28 Previous history of anxiety was self-reported in
the questionnaire in pregnancy week 18. Use of antidepres-
sants during pregnancy was self-reported in pregnancy weeks
18 and 30. A combined score of anxiety and depression (SCL-
5) was used in pregnancy week 18 to evaluate early pregnancy
psychiatric symptoms.
Statistical Analysis
IBM SPSS Statistics software version 26 was used to make
variables and imputations. Stata version 16 was used in the
remaining analyses.
The different MS groups were compared to a reference group
of all women without MS in MoBa. Matching was not per-
formed. Continuous variables were analyzed with Student t
test when normally distributed and skewed data with the
Mann-Whitney U test. Categorical variables were compared
with the Pearson χ2 test or with Fisher exact test if any cross-
table cell had an expected count <5. We analyzed the risk of
depression and anxiety by logistic regression with estimated
odds ratios (ORs) and 95% confidence intervals (CIs). OR
estimates were adjusted for the possible confounders age,
parity, overweight, and adverse socioeconomic factors (≥1 of
the following: single mother, low household income, or short
education). We accounted for clustering among women with
more than 1 pregnancy (n = 14,379) with robust standard
error estimations. Estimates with CIs not including 1 were
considered statistically significant.
Secondary Outcome
For women with diagnosed MS before pregnancy and women
in the reference group, we manually performed a backward
stepwise logistic regression analysis with third trimester de-
pression as the dependent variable and a list of 17 independent
variables as potential predictors (data available from Dryad,
table e-1, doi.org/10.5061/dryad.g4f4qrfpkv). The alpha to
enter the multivariate model was ≤0.1 and alpha for variable
removal was ≥0.05. To evaluate whether the predictors differed
between women with MS and the reference group we included
relevant interaction terms in the model.
Imputation of Missing Values
The missing values analysis procedure in SPSS with the
expectation-maximization algorithm was used to impute
missing values when some of the SCL or LTMD items were
not completed. Our requirements for imputation were that
maximum 1 in 5 items (20%) was missing in SCL-5 and
maximum 3 of the 8 (38%) in SCL-8. In LTMD, the first and
sixth item had to be completed, and maximum 2 of 6 items
(33%) missing to allow for imputation. If these requirements
were exceeded, the cases were set as missing.
Sensitivity Analyses
Various cutoff points for the subscales of HSCL-25 have been
suggested.19 We therefore did a sensitivity analysis of severe
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depression with a high cutoff for depression in the third tri-
mester, defined as SCL-4D score greater than the population
mean +2 SD.
One of the items in SCL-4D, “Have you been bothered by…
feeling everything is an effort?” can be interpreted as a proxy
of fatigue, which is a common symptom in MS.29 As MS-
related fatigue could influence this part of the depression
score, the distribution of the answers to this question was
analyzed with the χ2 and Fisher exact test, comparing the MS
groups with the reference group. The answers to this question
did not differ between women with MS diagnosis before
pregnancy and women without MS.
Standard Protocol Approvals, Registrations,
and Patient Consents
The establishment and initial data collection in MoBa were
based on a license from the Norwegian Data Protection
Agency and approval from the Regional Committees for
Medical and Health Research Ethics (REK). The MoBa co-
hort is regulated by the Norwegian Health Registry act.
The current study was approved by REK (reference 2016/
906). Written informed consent for use of the information in
research and for data linkage was obtained during enrollment
from all participants in MoBa and MSR.
Data Availability
Enquiries regarding access to data fromMoBa and theMBRN
can be directed to the Norwegian Institute of Public Health.




The cohort consisted of 114,629 pregnant women (figure 2).
Of these women, 546 were diagnosed with MS and divided
into 3 groups:
1. One hundred forty women were diagnosed with MS
before pregnancy
2. Ninety eight women were diagnosed with MS after
pregnancy and had symptom onset before pregnancy
3. Three hundred eight women were diagnosed with MS
after pregnancy and had symptom onset after pregnancy
Women who did not develop MS during the follow-up period
(n = 111,627) served as the reference group and had a median
follow-up time of 13 years (range 9–19).
Women in group 2 had experienced their first MS symptom
years or months before pregnancy (figure 1). However, they
were undiagnosed at inclusion and had a median time of 4
years to MS diagnosis after pregnancy (table 1). Women in
group 3 experienced their first MS symptom up to 17 years
after pregnancy, with a median of 6 years until symptom
onset. Median follow up-time for women with MS diagnosed
after pregnancy was 7 years (range 0–17).
The characteristics of women diagnosed with MS before
pregnancy and the reference group were similar for socio-
economic and lifestyle factors and previous anxiety and de-
pression (table 1). However, women diagnosed with MS
before pregnancy were older and more likely to receive dis-
ability benefits. Compared to the reference group, women
who had experienced MS symptoms but were not yet di-
agnosed with MS (group 2) more often had planned preg-
nancies and were more likely to smoke during pregnancy.
Women who had their first MS symptom after pregnancy
(group 3) were younger, more often overweight, more fre-
quently smoked during pregnancy, and had experienced more
physical or sexual abuse compared to the reference group.
Dropout rates in MoBa at 6 and 18 months postpartum
among the women who screened positive for depression in
the third trimester were similar for all examined groups (data
available from Dryad, table e-2, doi.org/10.5061/dryad.
g4f4qrfpkv).
Women Diagnosed With MS Before Pregnancy
A total of 15% of women diagnosed with MS before preg-
nancy had depression in the third trimester compared to 9%
in the reference group without MS (table 2). The crude OR
was 1.8 (95%CI, 1.1–2.9). The OR was 2.0 (95%CI, 1.2–3.1)
after adjusting for age, parity, overweight, and socioeconomic
factors.
The increased risk was confirmed in the sensitivity analysis
when we used a higher cutoff for depression: 8% of women
with diagnosed MS had severe depression compared to 4% in
the reference group, with adjusted OR (aOR) 2.2 (95% CI,
1.2–4.2).
There was no difference in depression point prevalence 6
months after birth between women diagnosed with MS and
the reference group. However, among the women with MS
who were depressed in the third trimester, 77% of those
responding to both questionnaires (n = 13) were still de-
pressed 6 months postpartum compared to 38% in the ref-
erence group (aOR, 5.2; 95% CI, 1.4–18.8). Nevertheless, the
proportion of women who had recovered from perinatal de-
pression 18 months postpartum was similar; 52% recovery for
women with MS diagnosis before pregnancy and 61% for
women in the reference group (aOR, 1.3; 95% CI, 0.5–2.9).
Among the women with perinatal depression, this repre-
sented their first-ever episode of depression in 50% with di-
agnosed MS and in 51% of the reference group (aOR, 1.3;
95% CI, 0.6–3.2).
Self-reported use of antidepressants during pregnancy did not
differ between the groups. Among the women diagnosed with
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pregnancy, n = 140









Age at inclusion, y 31 (4)n 30 (4) 28 (5)n 30 (5)
Paritya 1 (0–4) 1 (0–4) 1 (0–3) 1 (0–4)
Low household incomeb 5 (4) 5 (6) 22 (9) 7,402 (8)
Maternal short educationc 3 (2) 2 (2) 8 (3) 2,751 (3)
Single mother 5 (4) 3 (4) 5 (2) 2,371 (2)
Unplanned pregnancy 17 (13) 8 (9)m 57 (20) 19,486 (20)
Comorbidityd 5 (4) 9 (10) 21 (7) 7,452 (7)
Social security disabilitye 22 (17)n 0 (0) 8 (3) 1,653 (2)
Adverse life eventsf 49 (41) 30 (37) 87 (33) 30,462 (33)
Adverse pregnancy eventsg 40 (31) 28 (31) 77 (26) 28,702 (28)
Previous anxiety/depressionh 37 (26) 20 (20) 69 (22) 24,912 (22)
Physical/sexual abusei 20 (17) 17 (21) 58 (22)m 15,484 (17)
Smoking in pregnancy 13 (11) 14 (18)m 38 (15)m 8,405 (9)
Alcohol in pregnancyj 5 (4) 2 (2) 5 (2) 2,643 (3)
Prepregnancy BMI >25 43 (34) 30 (35) 101 (37)m 30,803 (31)
Depression/anxiety week 18k 20 (16) 6 (7) 38 (14) 10,682 (11)
MS characteristic
Age at diagnosis, y 26 (5) 34 (6) 37 (6) NA
Years with/until MS diagnosis 5 (0 to 21) −4 (−13 to 0) −8 (−17 to −1) NA
Years since/until onsetl of MS 7 (1 to 21) 2 (0 to 15) −6 (−17 to −1) NA
Years from onsetl to diagnosis 1 (0 to 16) 8 (0 to 22) 1 (0 to 11) NA
Type of MS NA
RRMS 115 (82) 91 (93) 298 (97)
PPMS 1 (<1) 4 (4) 4 (1)
Unspecified 24 (17) 3 (3) 6 (2)
Abbreviations: BMI = body mass index; MS = multiple sclerosis; NA = not applicable; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-
remitting multiple sclerosis.
Women were divided into 3 groups defined by their MS status in pregnancy. The reference group consisted of all women without MS diagnosis during the
follow-up period. The number may vary within the columns due to missing data. Categorical variables were compared with Pearson χ2 test or Fisher exact
test. Continuous variables were analyzedwith Student t test when normally distributed and skewed datawith theMann-WhitneyU test. Values aremean (SD),
median (range), or n (%).
a Number of all prior pregnancies >24 gestational weeks. Maximum value is 4, representing 4 or more.
b Total household income <60% of the cohort median income in the given measurement year.
c Maternal short education ≤9 years.
d Prepregnancy chronic diseases registered by health personnel in the Medical Birth Registry of Norway: asthma, prepregnancy hypertension, renal disease,
rheumatoid arthritis, type 1 diabetes, or epilepsy.
e Permanent social security disability or work assessment allowance funded by the government.
f ≥1 of the following: problems at work/study, financial problems, divorce/separation/breakup, conflict with family or friends, severe injury or illness to the
womanor a loved one, involvement in a severe traffic accident, fire or robbery, or death of a close relative or friend during the last 12months anddefining it as
“painful or difficult.”
g Prior history of stillbirth or miscarriages >12 weeks, prior or current preeclampsia, or first trimester vaginal bleeding.
h Self-reported history of anxiety or positive screening on the lifetime history of major depression score.
i Physical or sexual abuse during childhood or adulthood. Questions adapted from the Abuse Assessment Screen.
j Alcohol consumption ≥1 occasion per month during pregnancy.
k A combined score of depression and anxiety (Symptom Checklist 5) was used in pregnancy weeks 17–20.
l First MS symptom.
m Level of significance compared to the reference group p < 0.05.
n Level of significance compared to the reference group p < 0.001.
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MS and depression in the third trimester, 17% had used an-
tidepressants up to this time in pregnancy, compared to 12%
of the depressed women in the reference group (aOR, 1.2;
95% CI, 0.4–4.5).
There were no differences in point prevalence of anxiety be-
tween women with diagnosed MS and the reference group
during and after pregnancy.
Secondary Outcome
The backward stepwise logistic regression analysis identified
several predictors for depression in the third trimester in
women diagnosed with MS before pregnancy (table 3). In-
teraction analyses indicated a synergistic effect between MS
and adverse socioeconomic factors and MS and history of
sexual or physical abuse on the risk of depression. Previous
depression or anxiety did not modify the effect of MS on
depression. Recent MS diagnosis, MS type, and receiving
disability benefits were not predictors for depression (data
available from Dryad, table e-1, doi.org/10.5061/dryad.
g4f4qrfpkv).
Women Diagnosed With MS After Pregnancy
Women diagnosed with MS after pregnancy with symptom
onset before pregnancy (group 2) did not have increased
frequency of depression or anxiety in the perinatal period
(table 4).
Table 2 Depression and Anxiety in Women With Multiple Sclerosis (MS) Diagnosed Before Pregnancy and During the
Postpartum Period
MS diagnosed before pregnancy, n = 140 MS diagnosed postpartum, n = 35
Reference group, n = 111,627, n (%)N (%) OR (95% CI) p Value N (%) OR (95% CI) p Value
Depression
Third trimestera 18 (15)b 2.0 (1.2–3.1)b 0.006b 0 (0)b — 0.043b 8,410 (9)
6 months postpartum 16 (14) 1.5 (0.8–2.5) 0.182 7 (23)b 3.1 (1.3–7.2)b 0.010b 8,246 (10)
18 months postpartum 15 (17) 1.4 (0.8–2.5) 0.279 10 (42)b 5.0 (2.1–11.9)b <0.001b 8,333 (13)
Anxiety
Third trimestera 5 (4) 0.8 (0.4–2.0) 0.705 1 (3) 0.5 (0.1–4.1) 0.552 5,089 (6)
6 months postpartum 4 (4) 0.8 (0.3–2.2) 0.692 3 (10) 2.4 (0.7–7.7) 0.149 4,058 (5)
18 months postpartum 6 (7) 1.4 (0.6–3.2) 0.419 0 (0) — 0.640 3,591 (6)
Point prevalence of depression and anxiety from pregnancy until 18 months postpartum is shown. Adjusted p values and odds ratios (ORs) with 95%
confidence intervals (CIs) for depression and anxiety in women diagnosed with MS before pregnancy and in the postpartum period compared to women
without MS are shown. The number (n) may vary within the columns because of missing data. Depression and anxiety are defined as Hopkins Symptom
Checklist (SCL-4D and SCL-4A, respectively)mean >1.75. Estimates are adjusted for age, parity, overweight (bodymass index >25), and adverse socioeconomic
factors (single mother, low household income <60% of median, and short education ≤9 years).
a Pregnancy week 30.
b Statistically significant.
Table 3 Predictors for Third Trimester Depression in Women With Multiple Sclerosis (MS) Diagnosed Before Pregnancy
and Women Without MS
Predictor
MS (n = 140) Reference group (n = 111,627) Interaction term
MS × predictor,
p valuep Value OR (95% CI) (multivariable) p Value OR (95% CI) (multivariable)
Adverse socioeconomic factorsa 0.006 6.0 (1.7–28.0) <0.001 1.9 (1.7–2.0) 0.061
Sexual/physical abuseb 0.003 5.5 (1.8–17.5) <0.001 1.8 (1.7–1.9) 0.068
Previous depression/anxietyc 0.009 4.6 (1.5–14.6) <0.001 3.6 (3.4–3.8) 0.692
Odds ratios (ORs) with 95% confidence intervals (CIs) for predictors of depression in the third trimester in women with MS diagnosis before pregnancy and
women in the reference group are shown. We manually performed a backward stepwise logistic regression analysis within the group of women with MS
diagnosed before pregnancy, with third trimester depression as the dependent variable and 17 independent variables as potential predictors (data available
from Dryad, table e-1, doi.org/10.5061/dryad.g4f4qrfpkv). The alpha to enter the multivariate model was ≤0.1 and ≥0.05 for variable removal. Predictors
remaining in themodel are shown here. The final model was subsequently run on the reference group to compare estimates of ORs.We performed separate
backward stepwise logistic regression analyses on the reference group (data available from Dryad, figure e-1). The remaining predictors for the MS
population were included as interaction terms in logistic regression analyses on the entire population with third trimester depression as the dependent
variable with adjustment for age, parity, socioeconomic factors, and prepregnancy body mass index >25.
a Single mother, low household income <60% of median, or short education ≤9 years.
b Physical or sexual abuse during childhood or adulthood. Questions adapted from the Abuse Assessment Screen.
c Self-reported history of anxiety or positive screening on the lifetime history of major depression score.
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Among women with symptom onset after pregnancy
(group 3), those with their first MS symptom within 5 years
after pregnancy (n = 136) had higher frequency of de-
pression and anxiety in the third trimester compared to the
reference group (depression: 14% vs 9%, anxiety: 9% vs
6%) (table 4). In contrast, women with more than 5 years
to onset of symptoms (n = 172) did not have higher fre-
quency of depression or anxiety at any assessment in the
perinatal period.
Women Diagnosed With MS Postpartum
Thirty-five women were diagnosed with MS during the 18-
month postpartum period (figure 1). Although none of these
was depressed at the assessment in the third trimester, they
had a higher frequency of depression compared to the refer-
ence group both at 6 months (23% vs 10%) and at 18 months
postpartum (42% vs 13%) (table 2). There were no differ-
ences in point prevalences of anxiety between women with
postpartum MS diagnosis and the reference group. Median
time from symptom onset to diagnosis was 2 years (range
0–12) in women with postpartum depression in this group,
compared to 1 year (range 0–12) for this MS group as a
whole.
Women in the reference group who were diagnosed with
other chronic diseases in the postpartum period (n = 2,640)
more often had postpartum depression compared to the
remaining “healthy” proportion of the reference group, but
numerically lower than for women with postpartum MS di-
agnosis (figure 3). The aORs of postpartum depression in
women diagnosed with MS postpartum compared to women
diagnosed with other chronic diseases in the same period was
1.5 (95% CI, 0.6–3.4) at 6 months and 1.9 (95% CI, 0.8–4.2)
18 months postpartum.
Discussion
Our study found increased risk of depression during preg-
nancy in women with an established MS diagnosis. Fur-
thermore, women with MS and depression in pregnancy had
more prolonged depressive symptoms, lasting into the
postpartum period. However, the prognosis for recovery was
similar 18 months postpartum. Women who were diagnosed
with MS in the postpartum period had a high risk of post-
partum depression.
Table 4 Perinatal Depression and Anxiety in Women Diagnosed With Multiple Sclerosis (MS) After Pregnancy
Symptom onset before pregnancy, n = 98 Symptom onset after pregnancy, n = 308
Reference group,
n = 111,627, n (%)N (%) OR (95% CI)
≤5 years after
pregnancy, n = 136
>5 years after
pregnancy,a n = 172
N (%) OR (95% CI) N (%) OR (95% CI)
Depression
Third trimesterb 5 (6) 0.5 (0.2–1.4) 17 (14)c 1.9 (1.1–3.1)c 16 (11) 1.2 (0.7–2.0) 8,410 (9)
6 months postpartum 9 (11) 1.3 (0.6–2.6) 16 (14) 1.8 (0.99–3.1) 17 (12) 1.2 (0.7–2.0) 8,246 (10)
Anxiety
Third trimesterb 3 (4) 0.7 (0.2–2.2) 11 (9)c 2.0 (1.1–3.7)c 8 (6) 0.7 (0.3–1.6) 5,089 (6)
6 months postpartum 4 (5) 1.1 (0.4–3.1) 7 (6) 1.3 (0.6–3.0) 11 (8) 1.8 (0.9–3.2) 4,058 (5)
The number (n) may vary within the columns due to missing data.
Point prevalence of depression and anxiety from pregnancy until 6 months postpartum is shown. Adjusted p values and odds ratios (ORs) with 95%
confidence intervals (CIs) for depression and anxiety in women diagnosed withMS after pregnancy compared to a reference group of womenwithoutMS are
shown. Depression and anxiety are defined as Hopkins Symptom Checklist (SCL-4D and SCL-4A, respectively) mean >1.75. Estimates are adjusted for age,
parity, overweight (body mass index >25), and adverse socioeconomic factors (single mother, low income <60% of median, and short education ≤9 years).
a 6–17 years after pregnancy.
b Pregnancy week 30.
c Statistically significant.
Figure 3 Perinatal Depression in Women Diagnosed With
Multiple Sclerosis (MS) or Other Chronic Disease
in the Postpartum Period
Point prevalence of depression from pregnancy week 30 until 18 months
postpartum in women who were diagnosed with MS (n = 35) or another
chronic disease (n = 2,640) in the 18-month postpartum period. Women
without MS or another postpartum chronic diagnosis (n = 108,987) repre-
sents the reference group. Depression is defined as Hopkins Symptom
Checklist 4Dmean >1.75. N values are given for the first assessment and are
later lower due to missing data. Women who were pregnant 18 months
postpartum were excluded (figure 2).
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The use of validated questionnaires and a population-based
design in the current study extends previous knowledge on
perinatal depression in MS. We have identified one other
study on prevalence and risk estimations of perinatal de-
pression in people with MS. This other population-based
study found a 26% prevalence of perinatal depression or
anxiety in 255 women with MS, compared to 21% in 904
women without MS (OR, 1.28; 95% CI, 0.99–1.65).7 Our
point prevalence figures were lower (15% vs 9%), whereas the
risk estimate for depression in the third trimester for women
withMSwas higher in our study. The estimates are not strictly
comparable due to different methodology. We evaluated de-
pressive and anxiety symptoms separately and used several
assessments of point prevalence instead of period prevalence.
The previous study used diagnostic codes in addition to an-
tidepressant and anxiolytic prescriptions as proxies for de-
pression and anxiety.
The increased occurrence of depression during pregnancy in
women with an established MS diagnosis could be explained
by several factors. Perinatal depression is linked to dysregu-
lation of the maternal hypothalamic-pituitary-adrenal (HPA)
axis.30,31 The HPA axis is also involved in the mechanisms of
MS.32 The knowledge of having a severe and potentially
progressive disease may cause psychological distress. Un-
certainty and lack of hope are shown to be independent
predictors for depression in MS, regardless of disability sta-
tus.33 In addition, depression might be caused by in-
flammation3 or manifest lesions in the brain.34 All these
mechanisms can interact or have reciprocal effects.
In contrast to women with an establishedMS diagnosis before
pregnancy, women who were diagnosed with MS postpartum
had a substantially increased risk of postpartum depression.
Depressive symptoms in these women could be triggered by
disease awareness in a vulnerable period when caring for a
newborn baby. Women who were diagnosed with other
chronic diseases in the postpartum period also had higher
occurrence of depression, but not as marked as for women
diagnosed with MS. Many of these women with a recent MS
diagnosis probably had ongoing disease activity and in-
flammation, which may have contributed to the depressive
symptoms.3,35
We found low risk estimates for perinatal anxiety for women
with established MS. Previous studies have shown that de-
pression and anxiety probably have diverse attributable factors
and mechanisms in MS, which may explain why the risk esti-
mates differed. One study found correlation between in-
flammation and social and state anxiety, while trait anxiety was
associated with disease duration.3 Depression, but not anxiety,
has been associated with subsequent disability progression.36
Another study found an association between depression and
brain atrophy, but no association between anxiety and atrophy.34
Key predictors for pregnancy-related depression in women
with established MS in our study were adverse socioeconomic
factors, a history of sexual or physical abuse, and depression or
anxiety prior to pregnancy. The same predictors for perinatal
depression have previously been found in women with epi-
lepsy,24 and are also known predictors for perinatal de-
pression in the general maternal population.25,26 However,
the interaction analyses indicated a synergistic effect between
MS and adverse socioeconomic status and between MS and a
history of sexual or physical abuse. This means that having
experienced abuse or having adverse socioeconomic status
seemed to increase the risk of depression substantially more in
women with MS than in women without MS. Accordingly,
women with these risk factors need special attention and
follow-up.
Perinatal depression in womenwithMS requires intervention,
as it reduces quality of life, often leads to paternal de-
pression,37 and reduces adherence to MS treatment.38 It may
also influence the mother–infant bond negatively,39 and is
associated with higher risk of psychiatric disorders in
children.7,8
We found that women withMS symptom onset within 5 years
after pregnancy had increased risk of both depression and
anxiety during pregnancy. Conversely, women with more
than 5 years until onset of MS symptoms did not have any
increased risk. Depression and anxiety are recognized as parts
of MS prodromal syndrome.11,12 Previous studies in non-
pregnantMS populations have shown increased occurrence of
depression and anxiety 2 years before MS diagnosis40 and up
to 5–10 years before the first demyelinating event.12,13 The
risk gradually increased closer to the year of the first event.
Women who were yet to be diagnosed with MS who had
already experienced their first MS-associated symptom did not
show any increased frequencies of depression or anxiety in
pregnancy. Of note, they had the lowest rate of unplanned
pregnancies, which may protect against perinatal depression.41
Their median time from MS onset to diagnosis was 8 years
compared to only 1 year in the other 2 MS groups. This sug-
gests that this group had a different disease course with milder
onset symptoms, and thus later diagnostic attention.
Strengths of our study include a large and detailed population-
based dataset. Our database linkage resulted in a unique study
design that gave the opportunity to compare pregnant women
withMS in different stages of the disease both with the general
population and with women who contracted other chronic
diseases postpartum. The MS diagnosis was thoroughly vali-
dated in a nationwide collaboration with local neurology de-
partments. The data were prospectively collected with
longitudinal measurements of depression and anxiety with
validated screening tools.42 Sensitivity analyses confirmed
that depression in women with established MS was in-
dependent of fatigue, and our findings were valid with higher
cutoff for depression.The dropout rates among the depressed
women in the different MS groups and the reference group
were similar, which limits the possibility of attrition bias.
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There are some limitations to our study. Depression and
anxiety were not diagnosed by a physician. However, anon-
ymous questionnaires using the SCL screening tools have
previously been shown to more accurately capture psychiatric
symptoms than interviews.43 Screening positive on SCL
subscales has been predictive of subsequent hospitalization
with depression and dispensation of antidepressants.44
Women with psychological distress may have been less mo-
tivated to participate in the MoBa study. This potential bias
could underestimate the depression prevalence, but should
not influence the risk differences between women with and
without MS. Hence, the exposure–outcome associations
found in our study are generalizable to the maternal pop-
ulation. A moderate participation rate of 41% can result in a
slightly selected sample, but is as expected from population-
based cohorts.45 A study on selection bias in the MoBa cohort
found an underrepresentation of adverse socioeconomic ex-
posure variables in the participating women, which may give
biased estimates of exposure and outcome prevalence.46
Previous population-based studies in Norway with 90% par-
ticipation rates have found 9%–11% prevalence of perinatal
depression, scored with EPDS, from the second trimester in
pregnancy into the postpartum period.47-49 We found the
same prevalence in our reference group. Thus, a potential
selection bias seems to have minimal effect on the outcomes
in our study. Due to personal data protection regulations, we
received date of MS onset/diagnosis as well as birth year, but
we did not know date of birth. Hence, we could not estimate
the exact relation between MS onset and diagnosis to child-
birth for a subgroup of patients. A few women may have been
misclassified into the group “MS diagnosed after pregnancy
with symptom onset before pregnancy.”A total of 3–6 women
in this group could have been diagnosed with MS in late
pregnancy and a maximum of 25 women could have had their
symptom onset during pregnancy. We had no information on
MS severity such as the Expanded Disability Status Scale.
Furthermore, our material lacks MRI data and clinical in-
formation on MS disease activity to assess effect on de-
pression and its influence by inflammation. Breastfeeding may
influence postpartum depression,50 but information on
breastfeeding was not available in our dataset. We had limited
information on medication, both antidepressants and MS-
specific disease-modifying drugs. Further research that in-
cludes potential effects of these variables is necessary for the
understanding of pathobiologic mechanisms in perinatal de-
pression in MS.
The increased risk and prolonged duration of perinatal
depression in women with MS shown in this study should
lead to special attention with timely prevention and treat-
ment. Clinicians should be especially aware of signs of
depression in women diagnosed with MS in the postpartum
period.
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